Phase I Study of SM-11355 for Liver Cancer
Author Information
Author(s): Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, Tomita K
Primary Institution: Kumamoto University School of Medicine
Hypothesis
Can the novel lipophilic platinum complex SM-11355 be safely administered to patients with hepatocellular carcinoma who are refractory to cisplatin/lipiodol?
Conclusion
The study found that SM-11355 shows promise for treating hepatocellular carcinoma, with one complete response and one partial response among the patients.
Supporting Evidence
- One patient achieved a complete response and another a partial response.
- Adverse effects included nausea, vomiting, and pyrexia, but were generally mild.
- Patients had a history of cisplatin-lipiodol treatment that was ineffective in many cases.
Takeaway
Doctors tested a new cancer drug called SM-11355 on 11 patients with liver cancer, and it helped some of them feel better.
Methodology
Patients received SM-11355 via intra-arterial infusion, and their responses were evaluated based on tumor size and adverse effects.
Limitations
The study was small and included patients with advanced disease and a history of ineffective treatments.
Participant Demographics
Patients aged 20-75 with recurrent hepatocellular carcinoma, mostly male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website